Anya Jabour; Barton A. Myers; Brian Craig Miller; Daniel E. Sutherland; Diane Sommerville LUP - University of Georgia Press (2011) Pehmeäkantinen kirja
Kevin A. Ewing; Duke K. McCall; David R. Case; Marshall Lee Miller; Daniel M. Steinway; Karen J. Nardi; Christopher Bell Rowman & Littlefield (2019) Kovakantinen kirja
The objective of this third edition is to consolidate within a single text the most current knowledge, practical methods, and regulatory considerations pertaining to formulations development with poorly water-soluble molecules. A pharmaceutical scientist’s approach toward solubility enhancement of a poorly water-soluble molecule typically includes detailed characterization of the compound’s physiochemical properties, solid-state modifications, advanced formulation design, non-conventional process technologies, advanced analytical characterization, and specialized product performance analysis techniques. The scientist must also be aware of the unique regulatory considerations pertaining to the non-conventional approaches often utilized for poorly water-soluble drugs. One faced with the challenge of developing a drug product from a poorly soluble compound must possess at a minimum a working knowledge of each of the above mentioned facetsand detailed knowledge of most. In light of the magnitude of the growing solubility problem to drug development, this is a significant burden especially when considering that knowledge in most of these areas is relatively new and continues to develop.